1294 related articles for article (PubMed ID: 19192649)
1. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
2. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
3. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
King CR; Presti JC; Gill H; Brooks J; Hancock SL
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
[TBL] [Abstract][Full Text] [Related]
7. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
8. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
9. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy.
Tsai HK; Manola J; Abner A; Talcott JA; D'Amico AV; Beard C
Urol Oncol; 2005; 23(4):230-7. PubMed ID: 16018937
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.
Matzinger O; Duclos F; van den Bergh A; Carrie C; Villà S; Kitsios P; Poortmans P; Sundar S; van der Steen-Banasik EM; Gulyban A; Collette L; Bolla M;
Eur J Cancer; 2009 Nov; 45(16):2825-34. PubMed ID: 19682889
[TBL] [Abstract][Full Text] [Related]
12. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
13. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
[TBL] [Abstract][Full Text] [Related]
14. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
[TBL] [Abstract][Full Text] [Related]
15. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
16. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
Lee CM; Lee RJ; Handrahan DL; Sause WT
Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
[TBL] [Abstract][Full Text] [Related]
17. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
18. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
[TBL] [Abstract][Full Text] [Related]
19. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
[TBL] [Abstract][Full Text] [Related]
20. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
